CAS 1313725-88-0|Savolitinib

Introduction：Basic information about CAS 1313725-88-0|Savolitinib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Savolitinib BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Savolitinib
CAS Number	1313725-88-0	Molecular Weight	345.361
Density	1.6±0.1 g/cm3	Boiling Point	/
Molecular Formula	C₁₇H₁₅N₉	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
Synonym	More Synonyms

Savolitinib BiologicalActivity

Description	Savolitinib (AZD6094) ia highly potent and selective c-Met inhibitor with an IC50 of 5 nM.
Related Catalog	Signaling Pathways >>Protein Tyrosine Kinase/RTK >>c-Met/HGFRResearch Areas >>Cancer
References	[1]. Jia H, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577-89. [2]. Schuller A, et al. The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient derived xenograft models. Clin Cancer Res. 2015 Mar 16. pii: clincanres.2685.2014. [3]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27.

Description

Savolitinib (AZD6094) ia highly potent and selective c-Met inhibitor with an IC50 of 5 nM.

Related Catalog

Signaling Pathways >>Protein Tyrosine Kinase/RTK >>c-Met/HGFRResearch Areas >>Cancer

References

[1]. Jia H, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577-89.

[2]. Schuller A, et al. The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient derived xenograft models. Clin Cancer Res. 2015 Mar 16. pii: clincanres.2685.2014.

[3]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27.

Chemical & Physical Properties

Density	1.6±0.1 g/cm3
Molecular Formula	C₁₇H₁₅N₉
Molecular Weight	345.361
Exact Mass	345.145050
PSA	91.61000
LogP	0.54
Index of Refraction	1.833
InChIKey	XYDNMOZJKOGZLS-NSHDSACASA-N
SMILES	CC(c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
Storage condition	-20℃

Safety Information

Hazard Codes	N

Synonyms

HMPL-504

UNII:2A2DA6857R

1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine

Savolitinib

1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-

AZD-6094

Recommended......